BioNTech SE (BVMF:B1NT34)

BioNTech SE Statistics

Total Valuation

BioNTech SE has a market cap or net worth of BRL 112.28 billion. The enterprise value is 34.12 billion.

Market Cap	112.28B
Enterprise Value	34.12B

Important Dates

The last earnings date was Tuesday, May 5, 2026.

Earnings Date	May 5, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+1.91%
Shares Change (QoQ)	+3.81%
Owned by Insiders (%)	16.26%
Owned by Institutions (%)	20.07%
Float	110.05M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	6.65
PB Ratio	1.00
P/TBV Ratio	1.11
P/FCF Ratio	29.50
P/OCF Ratio	22.88
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-4.53
EV / Sales	2.09
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	8.97

Financial Position

The company has a current ratio of 8.80, with a Debt / Equity ratio of 0.02.

Current Ratio	8.80
Quick Ratio	8.11
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	0.48
Interest Coverage	-97.41

Financial Efficiency

Return on equity (ROE) is -6.66% and return on invested capital (ROIC) is -25.58%.

Return on Equity (ROE)	-6.66%
Return on Assets (ROA)	-4.18%
Return on Invested Capital (ROIC)	-25.58%
Return on Capital Employed (ROCE)	-7.31%
Weighted Average Cost of Capital (WACC)	11.66%
Revenue Per Employee	2.16M
Profits Per Employee	-964,757
Employee Count	7,807
Asset Turnover	0.13
Inventory Turnover	3.34

Taxes

In the past 12 months, BioNTech SE has paid 473.37 million in taxes.

Income Tax	473.37M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -15.55% in the last 52 weeks. The beta is 1.37, so BioNTech SE's price volatility has been higher than the market average.

Beta (5Y)	1.37
52-Week Price Change	-15.55%
50-Day Moving Average	30.22
200-Day Moving Average	33.94
Relative Strength Index (RSI)	34.50
Average Volume (20 Days)	2,300

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	1.91

Income Statement

In the last 12 months, BioNTech SE had revenue of BRL 16.87 billion and -7.53 billion in losses. Loss per share was -30.75.

Revenue	16.87B
Gross Profit	13.27B
Operating Income	-8.50B
Pretax Income	-7.06B
Net Income	-7.53B
EBITDA	-7.17B
EBIT	-8.50B
Loss Per Share	-30.75

Balance Sheet

The company has 82.44 billion in cash and 1.82 billion in debt, with a net cash position of 80.62 billion.

Cash & Cash Equivalents	82.44B
Total Debt	1.82B
Net Cash	80.62B
Net Cash Per Share	n/a
Equity (Book Value)	112.47B
Book Value Per Share	444.73
Working Capital	82.81B

Cash Flow

In the last 12 months, operating cash flow was 4.91 billion and capital expenditures -1.10 billion, giving a free cash flow of 3.81 billion.

Operating Cash Flow	4.91B
Capital Expenditures	-1.10B
Depreciation & Amortization	1.29B
Net Borrowing	-62.61M
Free Cash Flow	3.81B
FCF Per Share	n/a

Margins

Gross margin is 78.65%, with operating and profit margins of -50.35% and -44.64%.

Gross Margin	78.65%
Operating Margin	-50.35%
Pretax Margin	-41.83%
Profit Margin	-44.64%
EBITDA Margin	-42.47%
EBIT Margin	-50.35%
FCF Margin	22.55%

Dividends & Yields

BioNTech SE does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.91%
Shareholder Yield	-1.91%
Earnings Yield	-6.71%
FCF Yield	3.39%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on November 21, 2022. It was a forward split with a ratio of 2.

Last Split Date	Nov 21, 2022
Split Type	Forward
Split Ratio	2

Scores

BioNTech SE has an Altman Z-Score of 7.3 and a Piotroski F-Score of 3.

Altman Z-Score	7.3
Piotroski F-Score	3